The fact that the cancer is positive for HER2 will affect ... But in the later stages, those who have the HER2+ type have better survival rates than those with HER2-. Breast cancers that are ...

Enhertu plus Perjeta demonstrated improvement in progression-free survival versus standard treatment in HER2-positive ...

In the Phase III DESTINY-Breast09 trial, Enhertu (trastuzumab deruxtecan) and Perjeta (pertuzumab) significantly improved ...

AstraZeneca and Daiichi Sankyo are aiming to establish their star antibody-drug conjugate (ADC) Enhertu as a first-line ...

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

particularly in advanced stages of the disease where the five-year survival rate is 5% to 10%. 1 Current recommended first-line treatment for HER2 positive advanced gastric cancer with PD-L1 CPS ...

Atezolizumab may improve upon perioperative treatment with trastuzumab and chemotherapy in HER2+, locally advanced, resectable gastric or GEJ cancer, researchers say.

This three-drug combination is a standard first-line treatment for metastatic HER2-positive breast cancer. AstraZeneca and Daiichi Sankyo said the improvement in progression-free survival was ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic ...

New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...